ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food… Read more
ChengDa Pharmaceuticals Co. Ltd. - Asset Resilience Ratio
ChengDa Pharmaceuticals Co. Ltd. (301201) has an Asset Resilience Ratio of 11.71% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how ChengDa Pharmaceuticals Co. Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down ChengDa Pharmaceuticals Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥281.96 Million | 11.71% |
| Total Liquid Assets | CN¥281.96 Million | 11.71% |
Asset Resilience Insights
- Moderate Liquidity: ChengDa Pharmaceuticals Co. Ltd. has 11.71% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
ChengDa Pharmaceuticals Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare ChengDa Pharmaceuticals Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
High Sierra Technologies Inc
PINK:HSTI |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
Annual Asset Resilience Ratio for ChengDa Pharmaceuticals Co. Ltd. (2022–2024)
The table below shows the annual Asset Resilience Ratio data for ChengDa Pharmaceuticals Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 39.31% | CN¥957.65 Million | CN¥2.44 Billion | +5.85pp |
| 2022-12-31 | 33.46% | CN¥776.89 Million | CN¥2.32 Billion | -- |